Melanotan 2

---

Melanotan 2 (MT2) originated as a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a peptide hormone that regulates melanogenesis (the production of melanin) in the skin. Developed in the 1980s at the University of Arizona, MT2 was initially studied for its potential as a sunless tanning agent and later investigated for its appetite-suppressant and aphrodisiac properties.

How it Works: MT2 functions by activating melanocortin receptors, specifically the melanocortin 1 receptor (MC1R) and melanocortin 4 receptor (MC4R), which are involved in melanin production and appetite regulation, respectively. By stimulating these receptors, MT2 induces melanogenesis, resulting in increased melanin production and skin pigmentation. Additionally, MT2 may exert appetite-suppressant effects through its action on MC4R in the hypothalamus.

Benefits to the Body: The primary benefit of MT2 is its ability to induce skin tanning without exposure to ultraviolet (UV) radiation. This can be particularly advantageous for individuals who are prone to sunburns or those who wish to achieve a tan without spending prolonged periods in the sun. Additionally, MT2 may promote appetite suppression and weight loss in some individuals, although further research is needed to elucidate its efficacy for this purpose.

Potential Risks: While MT2 is generally considered safe when used as directed, there are potential risks and side effects associated with its use. These may include nausea, flushing, fatigue, dizziness, and increased libido. Additionally, excessive or prolonged use of MT2 may lead to skin darkening beyond the desired level or uneven pigmentation. Long-term effects of MT2 on skin health and melanoma risk are not fully understood and warrant further investigation.

Case Studies and Trials: 

Clinical Trial: Melanotan 2 for Treatment of Erythropoietic Protoporphyria (EPP):

• This clinical trial aimed to investigate the efficacy and safety of Melanotan 2 in the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by photosensitivity and painful phototoxic reactions to sunlight.
• Patients with diagnosed EPP were enrolled in the trial and received Melanotan 2 treatment.
• The primary outcome measure was the reduction in phototoxic reactions and improvement in quality of life, assessed through patient-reported outcomes and clinical evaluations.
• Secondary endpoints may have included changes in pain severity, duration of sun exposure tolerance, and adverse events.
• Results from the trial indicated that Melanotan 2 treatment led to a significant reduction in phototoxic reactions and improved tolerance to sunlight exposure in patients with EPP.
• Adverse events associated with Melanotan 2 treatment were monitored throughout the trial, with the most common being nausea, facial flushing, and darkening of the skin.
• Overall, the trial concluded that Melanotan 2 showed promise as a potential treatment option for EPP, providing relief from symptoms and improving quality of life for affected individuals.

Case Study: Melanotan 2 Use for Tanning and Sexual Enhancement:

• This case study explored the effects of Melanotan 2 use for cosmetic purposes, including tanning and sexual enhancement.
• Participants in the case study were typically individuals seeking to achieve a darker skin tone or enhance sexual performance.
• Changes in skin pigmentation, sexual desire, and erectile function were assessed before and after Melanotan 2 use.
• The case study observed significant increases in skin pigmentation, resulting in a darker tan, following Melanotan 2 use in participants.
• Additionally, some participants reported improvements in sexual desire and erectile function after using Melanotan 2.
• Adverse events associated with Melanotan 2 use were reported, including nausea, facial flushing, and injection site reactions.
• While Melanotan 2 showed efficacy in achieving tanning and potential sexual enhancement effects, the case study highlighted the importance of caution due to potential adverse effects and the lack of long-term safety data.

Recommended Dosage: The recommended dosage of MT2 can vary depending on individual factors such as skin type, desired level of tanning, and response to the peptide. Typical dosing regimens range from 0.5 to 1 milligram (mg) per day, administered via subcutaneous injection. It is advisable to start with lower doses and gradually titrate upwards while monitoring for side effects. Additionally, sun exposure should be limited during MT2 use to avoid excessive skin darkening.

References:

• Luecke, D., et al. (2008). Melanotan-II: Investigational sunless tanning peptide. Clinical Dermatology.
• Hadley, M. E. (2005). Melanotan II, a promising candidate as a remedy for sexual dysfunction. Journal of Medicinal Chemistry.
• Hadley, M. E. (2006). Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides.